Clinical trials: Prurigo Nodularis
Prurigo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN1 (NCT05755438)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 71 sites in United States, Argentina and 9 more
- Volunteers
- 204 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
PRISM Study-Pruritus Relief Through Itch Scratch Modulation
To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Participants were randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at…
- Trial name
- PRISM (NCT03497975)
- Testing
- Nalbuphine ER Tablets
- Where
- 70 sites in United States, Austria and 3 more
- Volunteers
- 353 people
- Sponsor
- Trevi Therapeutics
Prurigo Nodularis
A Study of Barzolvolimab in Patients With Prurigo Nodularis
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
- Trial name
- NCT06366750
- Testing
- barzolvolimab
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Celldex Therapeutics
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension…
- Trial name
- NCT05061693
- Testing
- INCB054707
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 146 people
- Sponsor
- Incyte Corporation
Pruritus, Prurigo Nodularis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
- Trial name
- NCT03677401
- Testing
- 5mg Serlopitant Tablets
- Where
- 40 sites in Austria, Germany and 1 more
- Volunteers
- 295 people
- Sponsor
- Vyne Therapeutics Inc.
Healthy Participants, Healthy Subjects
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
This study is the first-in-human (FIH) study of BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different…
- Conditions
- Healthy Participants, Healthy Subjects, Healthy Volunteers, Autoimmune Diseases
- Trial name
- NCT06342713
- Testing
- BGB-45035
- Where
- 13 sites in Australia, China and 1 more
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- BeiGene
Prurigo Nodularis, Nodularis Prurigo
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo
- Trial name
- NCT02174432
- Testing
- nalbuphine HCl ER
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Trevi Therapeutics
Prurigo Nodularis
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
- Trial name
- NCT04204616
- Testing
- Nemolizumab
- Where
- 164 sites in United States, Austria and 14 more
- Volunteers
- 500 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
- Trial name
- NCT06213831
- Testing
- Ruxolitinib Cream 1.5%
- Where
- 20 sites in United States
- Volunteers
- 23 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis (PN)
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of subjects with prurigo nodularis.
- Trial name
- NCT07883213
- Testing
- AK139
- Volunteers
- 132 people
- Sponsor
- Akeso
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
- Trial name
- NCT06516965
- Testing
- Povorcitinib
- Where
- 119 sites in United States, Australia and 9 more
- Volunteers
- 346 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
- Trial name
- RE-UNITE PN (NCT06988618)
- Where
- 51 sites in United States, Germany
- Volunteers
- 600 people
- Sponsor
- Galderma R&D
Pruritus, Prurigo Nodularis
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
Study of the long term safety of serlopitant for the treatment of pruritus in adults.
- Conditions
- Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
- Trial name
- NCT03540160
- Testing
- 5 mg Serlopitant Tablets
- Where
- 85 sites in United States, Austria and 2 more
- Volunteers
- 558 people
- Sponsor
- Vyne Therapeutics Inc.
Prurigo Nodularis
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of Stapokibart Injection in the treatment of subjects with prurigo nodularis, and observe…
- Trial name
- NCT06424470
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Keymed Biosciences Co.Ltd
Prurigo Nodularis, Nodularis Prurigo
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to…
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
- Trial name
- NCT02174419
- Testing
- nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- Trevi Therapeutics
Prurigo Nodularis
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- Trial name
- NCT04501666
- Testing
- Nemolizumab 30 mg
- Where
- 100 sites in United States, Austria and 8 more
- Volunteers
- 286 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: Screening period: 2 to 4 weeks. Treatment period: 24 weeks. Post-intervention follow-up period: 16 weeks.
- Trial name
- NCT06293053
- Testing
- Dupilumab
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
Prurigo Nodularis
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
- Trial name
- NCT02196324
- Testing
- serlopitant
- Where
- 15 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Vyne Therapeutics Inc.
Atopic Dermatitis
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by…
- Trial name
- ADMIRE (NCT05451316)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- AbbVie